Topics

Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement.

08:00 EDT 19th May 2019 | BioPortfolio

Summary of "Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement."

Individuals with chronic hepatitis B virus (HBV) infection or past exposure to HBV infection have a substantial risk of reactivation during immunosuppressive cancer therapy. HBV reactivation can lead to liver failure, cancer treatment interruption or death. Clinical concordance with screening and treatment guidelines is inconsistent in practice, and existing international guidelines are not specific to the Australian context. We developed an Australian consensus statement with infectious diseases, hepatology, haematology and oncology specialists to inform hepatitis B screening and antiviral management for immunocompromised patients with haematological and solid organ malignancies in Australia.

Affiliation

Journal Details

This article was published in the following journal.

Name: The Medical journal of Australia
ISSN: 1326-5377
Pages:

Links

DeepDyve research library

PubMed Articles [14128 Associated PubMed Articles listed on BioPortfolio]

Management of skin cancer in recipients of solid organ transplants.

Recent improvements in post-transplant care have led to an increased life expectancy for recipients of organ transplants. These patients require lifelong immunosuppression, which is associated with an...

Shoulder arthroplasty in patients with immunosuppression following solid organ transplantation.

The purpose was to determine the risk and outcomes of primary shoulder arthroplasties in patients with immunosuppression who had undergone solid organ transplantation.

Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection - a multinational survey.

There is no consensus on the optimal management of immunosuppression during bacterial infections among solid organ transplant recipients.

The Burden of Hepatitis E among Patients with Hematological Malignancies: a Retrospective European Cohort Study.

The burden of hepatitis E virus (HEV) infection has been scarcely reported among patients with haematological malignancy.

Characterising the risk of Hepatitis E virus infection in haematological malignancies: a UK prospective prevalence study.

Clinical Trials [10386 Associated Clinical Trials listed on BioPortfolio]

Interest of Routine Screening for Hepatitis B and C in Patients Receiving Chemotherapy for Solid Tumors

Immunosuppression induced by cancer treatment increases the risk of hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivations. These viral reactivations may be asymptomatic but can...

Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies

The aim of the study is to obtain immune reconsitutuion as well as reduction of infective episodes and disease relapse in patient with haematological malignancies who underwent SCT(and sub...

Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies

The purpose of this study is to determine whether the histone deacetylase inhibitor CHR-2845 is tolerated in patients with haematological diseases and lymphoid malignancies.

A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies

This study is a first-in-human (FIH) study which is required to understand the PK characteristics, MTD, and safety profile of NOV1601(CHC2014) in subjects with solid organ malignancies.

A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM)

MDR (multidrug resistant) gram-negative bacteria have emerged as an important cause of bloodstream infection in hospitalized patients, especially in immunocompromised hosts. It was previou...

Medical and Biotech [MESH] Definitions

INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).

A family of hepatotropic DNA viruses which contains double-stranded DNA genomes and causes hepatitis in humans and animals. There are two genera: AVIHEPADNAVIRUS and ORTHOHEPADNAVIRUS. Hepadnaviruses include HEPATITIS B VIRUS, duck hepatitis B virus (HEPATITIS B VIRUS, DUCK), heron hepatitis B virus, ground squirrel hepatitis virus, and woodchuck hepatitis B virus (HEPATITIS B VIRUS, WOODCHUCK).

An alkylating agent of value against both hematologic malignancies and solid tumors.

A species in the genus HEPATOVIRUS containing one serotype and two strains: HUMAN HEPATITIS A VIRUS and Simian hepatitis A virus causing hepatitis in humans (HEPATITIS A) and primates, respectively.

INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.

Quick Search


DeepDyve research library

Relevant Topics

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Searches Linking to this Article